Treatment naive, unresectable, HER2 negative gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, regardless of PD-L1 expression, were randomly assigned (1:1:1) to nivolumab plus chemotherapy (capecitabine and oxaliplatin or leucovorin, fluorouracil, and oxaliplatin), nivolumab plus ipilimumab, or chemotherapy alone. Here, ERBB2 is linked to esophageal adenocarcinoma.